Cargando…

Altered age‐linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHT‐preAD study) with high brain amyloid load

INTRODUCTION: An effective therapy has not yet been developed for Alzheimer's disease (AD), in part because pathological changes occur years before clinical symptoms manifest. We recently showed that decreased plasma DYRK1A identifies individuals with mild cognitive impairment (MCI) or AD, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Delabar, Jean M., Ortner, Marion, Simon, Stephanie, Wijkhuisen, Anne, Feraudet‐Tarisse, Cecile, Pegon, Jonathan, Vidal, Emma, Hirschberg, Yael, Dubois, Bruno, Potier, Marie‐Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331462/
https://www.ncbi.nlm.nih.gov/pubmed/32642550
http://dx.doi.org/10.1002/trc2.12046
Descripción
Sumario:INTRODUCTION: An effective therapy has not yet been developed for Alzheimer's disease (AD), in part because pathological changes occur years before clinical symptoms manifest. We recently showed that decreased plasma DYRK1A identifies individuals with mild cognitive impairment (MCI) or AD, and that aged mice have higher DYRK1A levels. METHODS: We assessed DYRK1A in plasma in young/aged controls and in elderly cognitive complainers with low (L) and high (H) brain amyloid load. RESULTS: DYRK1A level increases with age in humans. However, plasma from elderly individuals reporting cognitive complaints showed that the H group had the same DYRK1A level as young adults, suggesting that the age‐associated DYRK1A increase is blocked in this group. L and H groups had similar levels of clusterin. DISCUSSION: These results are reflective of early changes in the brain. These observations suggest that plasma DYRK1A and not clusterin could be used to classify elderly memory complainers for risk for amyloid beta pathology.